Stockscreener 앱 받기
1.55
3.33%
0.05
시간 외 거래:
1.55
Repare Therapeutics Inc 주식(RPTX)의 최신 뉴스
What analysts say about Repare Therapeutics Inc. stockRecord-breaking gains - jammulinksnews.com
Why Repare Therapeutics Inc. stock attracts strong analyst attentionFree Access to Community - Newser
What drives Repare Therapeutics Inc. stock priceFree AI-Backed Trading Signals - jammulinksnews.com
Repare Therapeutics Inc. Stock Analysis and ForecastUnprecedented growth rates - jammulinksnews.com
Is Repare Therapeutics Inc. a good long term investmentOutstanding capital returns - jammulinksnews.com
what makes repare therapeutics inc. stock price move sharplyLow Risk Profit Ideas - Newser
Layoff Tracker: Following Challenges With DMD Therapy, Sarepta Will Cut 500 Employees - BioSpace
Repare Therapeutics Jumps 15% After $10M Licensing Deal With Debiopharm - Yahoo Finance
How Repare Therapeutics Inc. stock performs during market volatilityBig Profit Small Risk Alerts - Newser
Repare Therapeutics Jumps 15% After $10M Licensing Deal With Deb - GuruFocus
Repare Therapeutics Licenses Lunresertib to Debiopharm for Worldwide Development. - AInvest
Deal Watch: Debiopharm Takes On Precision Oncology Drug From Repare Collab - insights.citeline.com
Repare inks licensing deal with Debiopharm for lunresertib - The Pharma Letter
Repare Therapeutics Jumps After Hours On $267M Global Licensing Deal With Debiopharm; Retail Traders Rush In - Stocktwits
how repare therapeutics inc. stock performs during market volatilityFast Moving Stock Alerts - Newser
Repare Therapeutics' Lunresertib Deal: A Strategic Pivot to Unlock Oncology Potential and Near-Term Catalysts - AInvest
Repare Therapeutics stock surges after $10M licensing deal with Debiopharm By Investing.com - Investing.com South Africa
What makes Repare Therapeutics Inc. stock price move sharplyHigh Reward Risk Balanced Trading - Newser
Repare Therapeutics stock surges after $10M licensing deal with Debiopharm - Investing.com Nigeria
Repare Therapeutics Inc. Enters Exclusive Worldwide Licensing Agreement with Debiopharm for Lunresertib - MarketScreener
Repare Therapeutics (RPTX) Secures Global Licensing Deal with Debiopharm | RPTX Stock News - GuruFocus
Repare Therapeutics enters exclusive worldwide licensing agreement with Debiopharm for Lunresertib - MarketScreener
Repare Therapeutics licenses PKMYT1 inhibitor to Debiopharm for $10 million - Investing.com Nigeria
Repare Therapeutics jumps on cancer drug licensing deal - TradingView
Repare Therapeutics Enters Exclusive Worldwide Licensing Agreement with Debiopharm for Lunresertib | RPTX Stock News - GuruFocus
Repare Therapeutics Enters Exclusive Worldwide Licensing Agreement with Debiopharm for Lunresertib - Business Wire
Repare Therapeutics (NASDAQ:RPTX) Trading Down 4.9%What's Next? - MarketBeat
Repare Therapeutics (NASDAQ:RPTX) Stock Price Down 4.9% – Should You Sell? - Defense World
Repare Therapeutics Out-Licenses Discovery Platforms to DCx Biotherapeutics in Strategic Deal - Insider Monkey
Is Repare Therapeutics, Inc. overvalued or undervalued? - MarketsMojo
Repare Therapeutics Holds Annual Shareholder Meeting - TipRanks
Millennium Management LLC Acquires 67,638 Shares of Repare Therapeutics Inc. (NASDAQ:RPTX) - Defense World
Repare Therapeutics (NASDAQ:RPTX) Shares Down 1.3%Here's Why - MarketBeat
Repare Therapeutics (NASDAQ:RPTX) Trading Down 1.3% – What’s Next? - Defense World
0.51%
자본화:
|
볼륨(24시간):